Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, HOOKIPA Pharma's Enterprise Value is $-19.45 Mil.
HOOKIPA Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was $-56.11 Mil. Therefore, HOOKIPA Pharma's EV-to-EBIT ratio for today is 0.35.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, HOOKIPA Pharma's Enterprise Value is $-19.45 Mil.
HOOKIPA Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was $-53.86 Mil. Therefore, HOOKIPA Pharma's EV-to-EBITDA ratio for today is 0.36.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, HOOKIPA Pharma's Enterprise Value is $-19.45 Mil.
HOOKIPA Pharma's Revenue for the trailing twelve months (TTM) ended in Jun. 2025 was $14.86 Mil. Therefore, HOOKIPA Pharma's EV-to-Revenue ratio for today is -1.31.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, HOOKIPA Pharma's Enterprise Value is $-19.45 Mil.
HOOKIPA Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was $-45.58 Mil. Therefore, HOOKIPA Pharma's EV-to-FCF ratio for today is 0.43.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
HOOKIPA Pharma (OTCPK:HOOK) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
HOOKIPA Pharma's current Enterprise Value is $-19.45 Mil.
HOOKIPA Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.11 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
HOOKIPA Pharma's current Enterprise Value is $-19.45 Mil.
HOOKIPA Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.86 Mil.
HOOKIPA Pharma's current Enterprise Value is $-19.45 Mil.
HOOKIPA Pharma's Revenue for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.86 Mil.
HOOKIPA Pharma's current Enterprise Value is $-19.45 Mil.
HOOKIPA Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.53 Mil.
HOOKIPA Pharma's current Enterprise Value is $-19.45 Mil.
HOOKIPA Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma Enterprise Value Related Terms
HOOKIPA Pharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for HOOKIPA Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOK vs LNAI, ZEOX, GDTC: Enterprise Value Comparison
For the Biotechnology subindustry, HOOKIPA Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
HOOKIPA Pharma's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma (HOOK) has a Enterprise Value of $-19.45 Mil as of Jun. 26, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on HOOKIPA Pharma and its competitors.
Is HOOKIPA Pharma's Enterprise Value too high?
HOOKIPA Pharma's current Enterprise Value is $-19.45 Mil. Overall, HOOKIPA Pharma has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Enterprise Value compare to LNAI and ZEOX?
HOOKIPA Pharma's Enterprise Value of $-19.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current Enterprise Value is $-19.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.78, compared to a current price of $1.15 — trading 58.6% below its estimated fair value. The current Enterprise Value is $-19.45 Mil. HOOKIPA Pharma's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Enterprise Value is $-19.45 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOOKIPA Pharma (HOOK) Overvalued in 2026?
Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued.
The current stock price of $1.15 is trading 58.6% below its estimated GF Value™ of $2.78.
GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.
Key valuation signals for HOOK:
Enterprise Value: $-19.45 Mil
GF Value™: $2.78 vs. price of $1.15 (58.6% below fair value)
No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
49GF Score
Get the complete analysis for HOOK
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 
